GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) Stock Competitors & Peer Comparison
See GLAXO.BO's competitors and their performance on the BSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GLAXO.BO and its BSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GLAXO.BO | ₹2,513.30 | +0.77% | 426B | 41.75 | ₹60.20 | +2.27% |
| CIPLA.NS | ₹1,408.40 | +1.11% | 1.1T | 29.39 | ₹47.99 | +2.06% |
| CIPLA.BO | ₹1,410.45 | +1.20% | 1.1T | 29.39 | ₹48.00 | +2.06% |
| ABBOTINDIA.BO | ₹27,758.20 | -3.40% | 595.6B | 37.81 | ₹740.55 | +2.34% |
| ABBOTINDIA.NS | ₹27,830.00 | -3.00% | 595.1B | 37.82 | ₹740.50 | +2.34% |
| GLAXO.NS | ₹2,506.50 | +0.46% | 425.9B | 41.52 | ₹60.56 | +2.27% |
| GLAND.NS | ₹2,422.00 | +1.86% | 392.6B | 38.13 | ₹62.42 | +1.60% |
| GLAND.BO | ₹2,407.40 | +1.26% | 392B | 38.11 | ₹62.40 | +1.60% |
| PFIZER.NS | ₹4,636.20 | -0.35% | 211.5B | 27.89 | ₹165.80 | +1.62% |
| PFIZER.BO | ₹4,625.20 | -0.85% | 211B | 27.85 | ₹165.80 | +1.62% |
Stock Comparison
Cipla Limited (NSE: CIPLA.NS)
GLAXO.BO vs CIPLA.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while CIPLA.NS trades at ₹1,408.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas CIPLA.NS's P/E ratio is 29.39. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to CIPLA.NS's ROE of +0.10%. Regarding short-term risk, GLAXO.BO is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check CIPLA.NS's competition here
Cipla Limited (BSE: CIPLA.BO)
GLAXO.BO vs CIPLA.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while CIPLA.BO trades at ₹1,410.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas CIPLA.BO's P/E ratio is 29.39. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to CIPLA.BO's ROE of +0.10%. Regarding short-term risk, GLAXO.BO is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check CIPLA.BO's competition here
Abbott India Limited (BSE: ABBOTINDIA.BO)
GLAXO.BO vs ABBOTINDIA.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, ABBOTINDIA.BO has a market cap of 595.6B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while ABBOTINDIA.BO trades at ₹27,758.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas ABBOTINDIA.BO's P/E ratio is 37.81. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to ABBOTINDIA.BO's ROE of +0.36%. Regarding short-term risk, GLAXO.BO is more volatile compared to ABBOTINDIA.BO. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check ABBOTINDIA.BO's competition here
Abbott India Limited (NSE: ABBOTINDIA.NS)
GLAXO.BO vs ABBOTINDIA.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, ABBOTINDIA.NS has a market cap of 595.1B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while ABBOTINDIA.NS trades at ₹27,830.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas ABBOTINDIA.NS's P/E ratio is 37.82. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to ABBOTINDIA.NS's ROE of +0.36%. Regarding short-term risk, GLAXO.BO is more volatile compared to ABBOTINDIA.NS. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check ABBOTINDIA.NS's competition here
GlaxoSmithKline Pharmaceuticals Limited (NSE: GLAXO.NS)
GLAXO.BO vs GLAXO.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, GLAXO.NS has a market cap of 425.9B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while GLAXO.NS trades at ₹2,506.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas GLAXO.NS's P/E ratio is 41.52. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to GLAXO.NS's ROE of +0.54%. Regarding short-term risk, GLAXO.BO is more volatile compared to GLAXO.NS. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check GLAXO.NS's competition here
Gland Pharma Limited (NSE: GLAND.NS)
GLAXO.BO vs GLAND.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, GLAND.NS has a market cap of 392.6B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while GLAND.NS trades at ₹2,422.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas GLAND.NS's P/E ratio is 38.13. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to GLAND.NS's ROE of +0.11%. Regarding short-term risk, GLAXO.BO is less volatile compared to GLAND.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check GLAND.NS's competition here
Gland Pharma Limited (BSE: GLAND.BO)
GLAXO.BO vs GLAND.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, GLAND.BO has a market cap of 392B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while GLAND.BO trades at ₹2,407.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas GLAND.BO's P/E ratio is 38.11. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to GLAND.BO's ROE of +0.11%. Regarding short-term risk, GLAXO.BO is more volatile compared to GLAND.BO. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check GLAND.BO's competition here
Pfizer Limited (NSE: PFIZER.NS)
GLAXO.BO vs PFIZER.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, PFIZER.NS has a market cap of 211.5B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while PFIZER.NS trades at ₹4,636.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas PFIZER.NS's P/E ratio is 27.89. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to PFIZER.NS's ROE of +0.18%. Regarding short-term risk, GLAXO.BO is more volatile compared to PFIZER.NS. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check PFIZER.NS's competition here
Pfizer Limited (BSE: PFIZER.BO)
GLAXO.BO vs PFIZER.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, PFIZER.BO has a market cap of 211B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while PFIZER.BO trades at ₹4,625.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas PFIZER.BO's P/E ratio is 27.85. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to PFIZER.BO's ROE of +0.18%. Regarding short-term risk, GLAXO.BO is more volatile compared to PFIZER.BO. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check PFIZER.BO's competition here
Marksans Pharma Limited (NSE: MARKSANS.NS)
GLAXO.BO vs MARKSANS.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, MARKSANS.NS has a market cap of 111.6B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while MARKSANS.NS trades at ₹257.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas MARKSANS.NS's P/E ratio is 26.63. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to MARKSANS.NS's ROE of +0.15%. Regarding short-term risk, GLAXO.BO is less volatile compared to MARKSANS.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check MARKSANS.NS's competition here
Marksans Pharma Limited (BSE: MARKSANS.BO)
GLAXO.BO vs MARKSANS.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, MARKSANS.BO has a market cap of 111.6B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while MARKSANS.BO trades at ₹256.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas MARKSANS.BO's P/E ratio is 26.62. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to MARKSANS.BO's ROE of +0.15%. Regarding short-term risk, GLAXO.BO is less volatile compared to MARKSANS.BO. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check MARKSANS.BO's competition here
Sanofi Consumer Healthcare India Ltd. (NSE: SANOFICONR.NS)
GLAXO.BO vs SANOFICONR.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, SANOFICONR.NS has a market cap of 107.7B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while SANOFICONR.NS trades at ₹4,675.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas SANOFICONR.NS's P/E ratio is 54.04. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to SANOFICONR.NS's ROE of +0.80%. Regarding short-term risk, GLAXO.BO is more volatile compared to SANOFICONR.NS. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check SANOFICONR.NS's competition here
Sanofi India Limited (BSE: SANOFI.BO)
GLAXO.BO vs SANOFI.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, SANOFI.BO has a market cap of 77.1B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while SANOFI.BO trades at ₹3,385.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas SANOFI.BO's P/E ratio is 20.70. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to SANOFI.BO's ROE of +0.39%. Regarding short-term risk, GLAXO.BO is more volatile compared to SANOFI.BO. This indicates higher risk in terms of short-term price fluctuations for GLAXO.BO.Check SANOFI.BO's competition here
Senores Pharmaceuticals Ltd. (NSE: SENORES.NS)
GLAXO.BO vs SENORES.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, SENORES.NS has a market cap of 63.9B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while SENORES.NS trades at ₹1,406.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas SENORES.NS's P/E ratio is 100.54. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to SENORES.NS's ROE of +0.14%. Regarding short-term risk, GLAXO.BO is less volatile compared to SENORES.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check SENORES.NS's competition here
SMS Pharmaceuticals Limited (NSE: SMSPHARMA.NS)
GLAXO.BO vs SMSPHARMA.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, SMSPHARMA.NS has a market cap of 35.7B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while SMSPHARMA.NS trades at ₹387.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas SMSPHARMA.NS's P/E ratio is 33.67. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to SMSPHARMA.NS's ROE of +0.14%. Regarding short-term risk, GLAXO.BO is less volatile compared to SMSPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check SMSPHARMA.NS's competition here
SMS Pharmaceuticals Limited (BSE: SMSPHARMA.BO)
GLAXO.BO vs SMSPHARMA.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, SMSPHARMA.BO has a market cap of 35.6B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while SMSPHARMA.BO trades at ₹387.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas SMSPHARMA.BO's P/E ratio is 33.64. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to SMSPHARMA.BO's ROE of +0.14%. Regarding short-term risk, GLAXO.BO is less volatile compared to SMSPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check SMSPHARMA.BO's competition here
NGL Fine-Chem Limited (NSE: NGLFINE.NS)
GLAXO.BO vs NGLFINE.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, NGLFINE.NS has a market cap of 19.8B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while NGLFINE.NS trades at ₹3,260.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas NGLFINE.NS's P/E ratio is 41.22. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to NGLFINE.NS's ROE of +0.16%. Regarding short-term risk, GLAXO.BO is less volatile compared to NGLFINE.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check NGLFINE.NS's competition here
NGL Fine-Chem Limited (BSE: NGLFINE.BO)
GLAXO.BO vs NGLFINE.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, NGLFINE.BO has a market cap of 19.7B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while NGLFINE.BO trades at ₹3,240.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas NGLFINE.BO's P/E ratio is 41.08. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to NGLFINE.BO's ROE of +0.16%. Regarding short-term risk, GLAXO.BO is less volatile compared to NGLFINE.BO. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check NGLFINE.BO's competition here
TTK Healthcare Limited (NSE: TTKHLTCARE.NS)
GLAXO.BO vs TTKHLTCARE.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, TTKHLTCARE.NS has a market cap of 14.8B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while TTKHLTCARE.NS trades at ₹1,089.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas TTKHLTCARE.NS's P/E ratio is 22.53. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to TTKHLTCARE.NS's ROE of +0.06%. Regarding short-term risk, GLAXO.BO is less volatile compared to TTKHLTCARE.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check TTKHLTCARE.NS's competition here
Kopran Limited (NSE: KOPRAN.NS)
GLAXO.BO vs KOPRAN.NS Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, KOPRAN.NS has a market cap of 9.6B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while KOPRAN.NS trades at ₹202.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas KOPRAN.NS's P/E ratio is 37.36. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to KOPRAN.NS's ROE of +0.05%. Regarding short-term risk, GLAXO.BO is less volatile compared to KOPRAN.NS. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check KOPRAN.NS's competition here
Kopran Limited (BSE: KOPRAN.BO)
GLAXO.BO vs KOPRAN.BO Comparison July 2026
GlaxoSmithKline Pharmaceuticals Limited (BSE: GLAXO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GLAXO.BO stands at 426B. In comparison, KOPRAN.BO has a market cap of 9.4B. Regarding current trading prices, GLAXO.BO is priced at ₹2,513.30 on the BSE, while KOPRAN.BO trades at ₹202.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GLAXO.BO currently has a P/E ratio of 41.75, whereas KOPRAN.BO's P/E ratio is 37.08. In terms of profitability, GLAXO.BO's ROE is +0.54%, compared to KOPRAN.BO's ROE of +0.05%. Regarding short-term risk, GLAXO.BO is less volatile compared to KOPRAN.BO. This indicates lower risk in terms of short-term price fluctuations for GLAXO.BO.Check KOPRAN.BO's competition here